2025-04-01 03:09:27
Latest Post
Infosys and Linux Foundation Networking Collaborate to Strengthen Responsible AI for Global Networks
ITC announces strategic acquisition of Pulp & Paper Undertaking of Aditya Birla Real Estate Limited
AGI Greenpac Ltd approves ~ Rs. 700 crore capex
NHPC Ltd updates on 300 MW Bikaner Solar Power Project
Prashant India Ltd enters into agreement for sale with Shantilon Poly Pvt Ltd
Stock Report
Bliss GVS Pharma Ltd Q2FY23 consolidated profit lower at Rs. 13.85 crores
Posted On : 2022-11-07 20:40:50( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 174.5810 crores during the period ended September 30, 2022 as compared to Rs. 195.6725 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 13.8538 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 25.7193 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 1.31 for the period ended September 30, 2022 as compared to Rs. 2.44 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 174.5810 crs | ₹195.6725 crs |  -10.78% |
| Net Profit | ₹13.8538 crs | ₹25.7193 crs | -46.13% |
| EPS | ₹1.31 | ₹2.44 | -46.31% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 174.5810 crores during the period ended September 30, 2022 as compared to Rs.201.4374 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.13.8538 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.21.2662 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.1.31 for the period ended September 30, 2022 as compared to Rs.2.01 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 174.5810 crs | ₹201.4374 crs | -13.33% |
| Net Profit | ₹13.8538 crs | ₹21.2662 crs | -34.86% |
| EPS | ₹1.31 | ₹2.01 | -34.83% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.370.2535 crores during the 6 Months period ended September 30, 2022 as compared to Rs.377.40 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.39.5731 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.45.5204 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.3.75 for the 6 Months period ended September 30, 2022 as compared to Rs.4.30 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹370.2535 crs | ₹377.40 crs | -1.89% |
| Net Profit | ₹39.5731 crs | ₹45.5204 crs | -13.07% |
| EPS | ₹3.75 | ₹4.30 | -12.79% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 77.15 as compared to the previous close of Rs. 75.60. The total number of shares traded during the day was 19602 in over 509 trades.
The stock hit an intraday high of Rs. 77.75 and intraday low of 75.90. The net turnover during the day was Rs. 1510370.00.
